Status:
COMPLETED
Immunophenotyping of Plasma Cells and Immune Effector Cells in Peripheral Whole Blood and Bone Marrow Samples From Multiple Myeloma (MM) Patients
Lead Sponsor:
Assistance Publique Hopitaux De Marseille
Conditions:
Multiple Myeloma
Eligibility:
All Genders
18+ years
Brief Summary
The objective of this study is to evaluate the immune profile of plasma cells and immune effector cells in paired peripheral whole blood and bone marrow samples from MM patients by standardized flow c...
Detailed Description
Study the biomarkers recorded on plasma cells and normal leukocytes including T lymphocytes (naïve, effectors and memories), B lymphocytes, Treg, NK, monocytes as well as their activation markers (CD2...
Eligibility Criteria
Inclusion
- Multiple myeloma without treatment
Exclusion
- \-
Key Trial Info
Start Date :
October 4 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 23 2023
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT05428163
Start Date
October 4 2022
End Date
May 23 2023
Last Update
November 8 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
APHM
Marseille, France